Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs

Abstract

Diabetes mellitus is a growing public health concern in the US and worldwide. Insulin therapy is the cornerstone of diabetes therapy, and the use of basal insulins will increase as clinicians strive to help their patients reach glycemic goals. Basal insulins have been continually improved upon over the years, and the long-acting basal insulin analogs, glargine and detemir, have many pharmacokinetic and pharmacodynamic advantages over neutral protamine Hagedorn insulin, namely, less variable absorption profiles, a less pronounced peak in effect, and a longer duration of action. Overall, glargine and detemir do not differ greatly in their safety and efficacy profiles. Major differences between the two include lower within-subject variability, lower risk of hypoglycemia, and a weight-sparing effect with insulin detemir. This review summarizes data from the key pharmacokinetic and pharmacodynamic studies, as well as clinical and observational studies to elucidate the role of each basal insulin analog in therapy.

Keywords:

• glargine
• detemir
• safety
• hypoglycemia
• weight
• glucose variability

Acknowledgements

The authors would like to acknowledge Dawn Clark, MSN, ANP-BC and Gary Wolfe, RN, CCM for their assistance in the critical review of the manuscript.

Disclosure

Dr Poon reports no conflict of interest in this work. Dr King has been a speaker for and has received research funding from Novo-Nordisk, Lilly, and sanofi-aventis.